388574-65-0

Usage

Uses

Used in Pharmaceutical Research:
2-Chloro-1-(4-trifluoromethyl-benzyl)-1H-benzimidazole is used as a research compound for exploring its potential biological properties and interactions with biological targets. Its unique structure allows for the investigation of its therapeutic benefits in various applications.
Used in Anticancer Applications:
In the field of oncology, 2-Chloro-1-(4-trifluoromethyl-benzyl)-1H-benzimidazole is used as a potential anticancer agent. Its specific interactions with biological targets may contribute to the inhibition of tumor growth and the treatment of various types of cancer.
Used in Treatment of Microbial and Parasitic Infections:
2-Chloro-1-(4-trifluoromethyl-benzyl)-1H-benzimidazole is also used in the development of treatments for microbial and parasitic infections. Its unique structure and potential biological properties make it a promising candidate for the development of new therapeutic agents in this area.

Upstream product

• 4857-06-1 2-chloro-1H-benzoimidazole 
• 939-99-1 4-trifluoromethylbenzyl chloride 
• 402-49-3 4-bromomethyltrifluoromethylbenzene 
• 913267-53-5 1-(4-trifluoromethylbenzyl)-1,3-dihydro-benzoimidazol-2-one 

Downstream Products

• 388575-17-5 [3,4-dioxo-10-(4-trifluoromethyl-benzyl)-3,4-dihydro-10H-benzo[4,5]imidazo[2,1-c][1,2,4]triazin-2-yl]-acetic acid ethyl ester 
• 388575-04-0 10-(4-trifluoromethyl-benzyl)-2,10-dihydro-benzo[4,5]imidazo[2,1-c][1,2,4]triazine-3,4-dione 
• 388574-84-3 [1-(4-trifluoromethyl-benzyl)-1H-benzoimidazol-2-yl]-hydrazine 

Relevant academic research and scientific papers

Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains Inhibit Microtubule and Hemozoin Formation: Structure-Activity Relationship and in Vivo Oral Efficacy Studies

A novel series of antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains at the C2 position, which possess dual asexual blood and sexual stage activities, is presented. Structure-activity relationship studies revealed that the 1-benzylbenzimidazole analogues possessed submicromolar asexual blood and sexual stage activities in contrast to the 1H-benzimidazole analogues, which were only active against asexual blood stage (ABS) parasites. Further, the former demonstrated microtubule inhibitory activity in ABS parasites but more significantly in stage II/III gametocytes. In addition to being bona fide inhibitors of hemozoin formation, the 1H-benzimidazole analogues also showed inhibitory effects on microtubules. In vivo efficacy studies in Plasmodium berghei-infected mice revealed that the frontrunner compound 41 exhibited high efficacy (98% reduction in parasitemia) when dosed orally at 4 × 50 mg/kg. Generally, the compounds were noncytotoxic to mammalian cells.

Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a] benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi

A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.

Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a] benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi

A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 mM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.

[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: A new class of selective aldose reductase inhibitors

Acetic acid derivatives of [1,2,4]triazino[4,3-a]benzimidazole (TBI) were synthesized and tested in vitro and in vivo as a novel class of aldose reductase (ALR2) inhibitors. Compound 3, (10-benzyl[1,2,4]triazino[4,3-a]benzimidazol-3,4(10H)-dion-2-yl)aceti